Gluten-related conditions, including celiac disease, wheat allergy, and non-celiac gluten sensitivity, may produce identical symptoms, making accurate diagnosis challenging. When medically necessary, this testing will provide clinicians useful diagnostics to determine the specific cause of symptoms reported as a gluten sensitivity.
The True Health Celiac Disease and Gluten Sensitivity Profile incorporates seven FDA-approved specific wheat-based serologic markers that can differentiate wheat allergy, celiac disease, and non-celiac gluten sensitivity.
Biomarkers included are available to order as individual tests, or as a comprehensive profile to help provide simultaneous diagnostic information about multiple conditions in a single blood draw.
Results from True Health's comprehensive testing offer a gateway to additional clinical assessment and effective patient management.
True Health Group is focused on transforming patient care through integrated diagnostics and healthcare services. True Health Diagnostics, a subsidiary, specialises in earlier-stage diagnosis and prevention of chronic disease, including cardiovascular, diabetes, cancer, genetic disorders, autoimmune disease, and more.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults